Head-To-Head Survey: Transenterix (TRXC) and Exactech (EXAC)

Transenterix (NASDAQ: TRXC) and Exactech (NASDAQ:EXAC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Transenterix and Exactech’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Transenterix $5.05 million 43.53 -$47.82 million N/A N/A
Exactech $262.96 million 1.66 $43.51 million $0.04 761.44

Exactech has higher revenue and earnings than Transenterix.

Analyst Recommendations

This is a breakdown of recent ratings for Transenterix and Exactech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Transenterix 0 1 0 0 2.00
Exactech 0 0 1 0 3.00

Transenterix presently has a consensus target price of $0.70, indicating a potential downside of 52.70%. Given Transenterix’s higher possible upside, analysts clearly believe Transenterix is more favorable than Exactech.

Insider and Institutional Ownership

64.6% of Exactech shares are owned by institutional investors. 28.3% of Exactech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Transenterix and Exactech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Transenterix -928.85% -49.16% -33.51%
Exactech 0.30% 7.39% 5.98%

Summary

Exactech beats Transenterix on 9 of the 11 factors compared between the two stocks.

About Transenterix

TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.

About Exactech

Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines. The Company distributes joint replacement systems, including knee, hip, spine and extremity implant systems, and biologic products and services and bone cement materials used in orthopedic surgery and dental procedures. The Exactech Knee System provides solutions for partial, primary and revision total knee arthroplasty. Its hip solutions address the continuum of hip arthroplasty. It manufactures and distributes various products and services designed for the healing and regeneration of bone and soft tissue, including products, which contain human allograft.

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply